|
Phase III CANVAS Trial Results Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes
Janssen Research & Development announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for Type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
BusinessWire |
Register Now
Archives